Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics is down 19.5% since the beginning of the year, and at $11.43 per share, it is trading 76.4% below its 52-week high of $48.45 from February 2024.

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know.

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

--Following a comprehensive search process, 10 x Genomics, Inc., today announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. "Jim's deep experience driving ...

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

10x Genomics (NASDAQ: TXG) is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, ...

10x Genomics employed 584 workers worldwide at the end of 2019, 852 people at the end of 2020, 1,239 people at the end of 2021 and 1,243 at the end of 2022, the SEC filings showed.

The case is 10x Genomics Inc v. Curio Bioscience Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-01375. For 10x: Matthew Powers, Paul Ehrlich, Stefani Smith and Robert Gerrity ...